# Hoffmann-La Roche: Phase 4 study closed enrollment, 19 enrolled (Muscular Atrophy, Spinal)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy |
| NCT ID | NCT05861999 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | Muscular Atrophy, Spinal |
| Intervention types | drug |
| Target enrollment | 19 |
| Site countries | United States, Germany, Israel, Poland, Qatar, United Kingdom |
| Posted | 2023-05-17 |
| Planned start | 2024-08-14 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05861999). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.